176 results match your criteria: "Hospital Nuestra Señora de Sonsoles[Affiliation]"

Community-acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large-scale, real-world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA-EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023-2024 autumn-winter season.

View Article and Find Full Text PDF

Cost-benefit analysis of the National Immunization Program in Spain.

Hum Vaccin Immunother

December 2024

IBIMA Platform Bionand, Universidad de Málaga - IBIMA Platform Bionand, Málaga, Spain.

Article Synopsis
  • The study analyzes the cost-benefit of Spain's National Immunization Program (NIP) and an expanded version, focusing on the long-term benefits of vaccinating newborns over their lifetime.
  • Using Excel for the analysis, the researchers estimated costs of €168.5 million for the 2020 NIP and €275.5 million for the expanded NIP, with potential economic benefits of €772.2 million and €803.0 million, respectively.
  • The benefit-cost ratios were found to be €4.58 for the 2020 NIP and €2.91 for the expanded NIP, indicating that vaccination programs are an effective public health strategy that provides significant societal economic returns.
View Article and Find Full Text PDF

Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study.

Breast

October 2024

Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA), Sao Paulo, Brazil; Hospital Arnau de Vilanova, FISABIO, Valencia, Spain; Universidad Católica de Valencia, Valencia, Spain.

Purpose: To evaluate the efficacy and safety of the combination of olaparib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC) and germinal BRCA mutations (gBRCAm).

Methods: OPHELIA (NCT03931551) was a single-arm, open-label, phase 2 clinical trial. Patients aged ≥18 years diagnosed with HER2-positive ABC with germinal deleterious mutations in BRCA1 or BRCA2 who had received at least one prior systemic regimen for advanced disease were enrolled.

View Article and Find Full Text PDF

Fluconazole-resistant Candida parapsilosis: fast detection of the Y132F ERG11p substitution, and a proposed microsatellite genotyping scheme.

Clin Microbiol Infect

November 2024

Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Faculty of Health Sciences - HM Hospitals, Universidad Camilo José Cela, Madrid, Spain.

Article Synopsis
  • This study aims to quickly and accurately detect the Y132F ERG11p mutation in Candida parapsilosis isolates and to analyze genetic diversity among these isolates for better tracking of fluconazole resistance.!* -
  • The research involved 223 isolates from patients across 20 hospitals in Spain and Italy, using newly optimized PCR methods that require no DNA extraction and provide results in as little as 1.5 hours.!* -
  • The findings confirm both PCR methods have 100% specificity and sensitivity, with Scheme 1 showing greater genetic diversity compared to Scheme 2, suggesting the use of specific microsatellite markers for better genotyping of resistant strains.!*
View Article and Find Full Text PDF

The blood vessel lumen is an extremely rare location for a benign peripheral nerve sheath tumor like schwannoma. Less than 10 cases have been previously reported. In this report, we present a case of a 68-year-old woman who had a soft tissue nodule at the posterior calf of her left leg during a physical examination.

View Article and Find Full Text PDF

Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study.

Lancet Haematol

August 2024

Hospital Universitario Morales Meseguer, Murcia, Spain; Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-ISCIII, Murcia, Spain.

Background: Inferior vena cava agenesis (IVCA) is a rare anomaly predisposing affected people to lower-limb venous thrombosis with low frequency of pulmonary embolism. Antenatal thrombosis and inherited thrombophilia have been suggested as causes of IVCA. However, there is little evidence on the clinical course and management of this condition.

View Article and Find Full Text PDF
Article Synopsis
  • Light-chain amyloidosis (AL) is a rare condition where misfolded proteins build up in various organs, commonly affecting the heart, with 50-70% of patients showing symptoms at diagnosis.
  • A study analyzed 67 patients diagnosed with advanced cardiac AL to identify factors that influence overall survival (OS).
  • Key findings include that better OS is correlated with a performance status score (ECOG PS) of 1 or lower, a heart function classification (NYHA FC) of 2 or lower, and achieving specific responses to treatment (hematological and cardiac) after initial therapy.
View Article and Find Full Text PDF

Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry.

Haematologica

August 2024

Miloš Mladenović, ;Charlotte Flasshove, Bojana Mišković, ;José-María Ribera-Santasusana, Martin Hoenigl, Juergen Prattes, Malgorzata Mikulska, Annarosa Cuccaro, Emel Bekirova, Josip Batinić, ;Nick De Jonge, Tatjana Adžić-Vukičević, ;Ľuboš Drgoňa, Hans Martin Orth, Florian Reizine, Monica Piedimonte, Jörg Schubert, Andrés Soto-Silva, Jorge Loureiro-Amigo, Laura Serrano, Lisset Lorenzo De La Peña, Anna Guidetti, Irati Ormazabal-Vélez, Sandra Malak, Maria Calbacho, Noemí Fernández, Rafael F. Duarte, Elizabeth De Kort, Guldane Cengiz Seval, Luisa Verga, Rui Bergantim, María-Josefa Jiménez-Lorenzo, Johan Maertens, Nina Khanna, Matthias Egger, Omar-Francisco Coronel-Ayala, Przemyslaw Zdziarski, Alessandro Busca, Elena Busch, Christian Bjørn Poulsen, François Danion, Tania Cushion, Sergio Pinzón, Yung Gonzaga, Austin Kulasekararaj, Hossein Zarrinfar, Baerbel Hoell-Neugebauer, Chi Shan Kho, Rémy Duléry, Martin Kolditz, Monica Fung, Alina Daniela Tanase.

View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic has severely affected individuals with hematological malignancies due to their weakened immune systems, resulting in higher mortality rates and severe outcomes.
  • Data from the EPICOVIDEHA registry, which compiles COVID-19 cases from these patients worldwide, was collected from 2020 to 2022, including 8,767 cases from 152 centers across 41 countries.
  • Findings show a significant drop in critical infections and overall mortality rates, but hospitalization (especially in ICU) remains a serious risk factor; vaccination is linked to better survival outcomes, highlighting the need for ongoing monitoring and support for these patients.
View Article and Find Full Text PDF

Background: Fluconazole-resistant Candida parapsilosis is a matter of concern.

Objectives: To describe fluconazole-resistant C. parapsilosis genotypes circulating across hospitals in Spain and Rome and to study their azole-resistance profile associated with ERG11p substitutions.

View Article and Find Full Text PDF

Background: Erythropoiesis stimulating agents (ESAs) are the first-line therapy in patients with lower-risk myelodysplastic syndromes (LR-MDS). Some predictive factors for ESAs response have been identified. Type and number of somatic mutations have been associated with prognosis and response to therapies in MDS patients.

View Article and Find Full Text PDF

Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world.

View Article and Find Full Text PDF

Introduction: Trastuzumab emtansine (T-DM1) significantly improves invasive disease-free survival and reduces the risk of recurrence in patients with HER2-positive early breast cancer (EBC) with residual disease (RD). The KARMA study aimed to describe the characteristics and management of these patients in clinical practice in Spain.

Material And Methods: We conducted a multicentre retrospective study in patients with HER2-positive EBC with RD following neoadjuvant treatment (NeoT) and who had received ≥1 dose of T-DM1 as adjuvant treatment.

View Article and Find Full Text PDF

Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis.

View Article and Find Full Text PDF

Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings.

Int J Infect Dis

December 2023

Hematology Unit, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Rome, Italy; Hematology Unit, Università Cattolica del Sacro Cuore, Rome, Italy.

Objectives: Elderly patients with hematologic malignancies face the highest risk of severe COVID-19 outcomes. The infection's impact on different age groups remains unstudied in detail.

Methods: We analyzed elderly patients (age groups: 65-70, 71-75, 76-80, and >80 years old) with hematologic malignancies included in the EPICOVIDEHA registry between January 2020 and July 2022.

View Article and Find Full Text PDF
Article Synopsis
  • - A study analyzing 165 multiple myeloma (MM) patients found that those who developed second primary malignancies (SPMs), particularly hematological ones, generally had a shorter survival time and were more likely to have had previous cancer treatments.
  • - Patients with hematological SPMs tended to be younger and had a higher rate of prior autologous hematopoietic cell transplantation, with treatment often stopped upon SPM detection, especially in cases of hemato-SPM.
  • - Overall survival (OS) post-SPM detection was only 8.5 months, with the main cause of death being the SPM; hence, regular monitoring and early intervention are crucial for improving patient outcomes.
View Article and Find Full Text PDF

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.

Int J Antimicrob Agents

October 2023

University of Cologne, Faculty of Medicine, and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; University of Cologne, Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany; University of Cologne, Faculty of Medicine, and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany; University of Cologne, Faculty of Medicine, and University Hospital Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany. Electronic address:

Introduction: Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections and decrease hospitalisation and mortality rates. Nirmatrelvir/ritonavir was authorised in Europe in December 2021, whereas molnupiravir is not yet licensed in Europe as of February 2022. Molnupiravir may be an alternative to nirmatrelvir/ritonavir because it is associated with fewer drug-drug interactions and contraindications.

View Article and Find Full Text PDF

Accurately diagnosing specific variants of alopecia remains challenging for pathologists, potentially delaying appropriate therapeutic decisions by dermatologists. Issues such as limited knowledge on optimal biopsy types and processing methods add complexity. Understanding the normal histology of hair follicles and their changes throughout the follicular cycle further complicates microscopic evaluation.

View Article and Find Full Text PDF

Background: To date, azoles represent the only viable option for oral treatment of invasive Candida infections, while rates of azole resistance among non-albicans Candida spp. continue to increase. The objective of this sub-analysis of the European multicenter observational cohort study Candida III was to describe demographical and clinical characteristics of the cohort requiring prolonged hospitalization solely to complete intravenous (iv) antifungal treatment (AF Tx).

View Article and Find Full Text PDF

Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study.

Lancet Infect Dis

June 2023

Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany; Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, and European Confederation of Medical Mycology Excellence Center for Medical Mycology, University of Cologne, Cologne, Germany; Centre for Molecular Medicine Cologne, University of Cologne, Cologne, Germany; Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.

Background: The European Confederation of Medical Mycology (ECMM) collected data on epidemiology, risk factors, treatment, and outcomes of patients with culture-proven candidaemia across Europe to assess how adherence to guideline recommendations is associated with outcomes.

Methods: In this observational cohort study, 64 participating hospitals located in 20 European countries, with the number of eligible hospitals per country determined by population size, included the first ten consecutive adults with culture-proven candidaemia after July 1, 2018, and entered data into the ECMM Candida Registry (FungiScope CandiReg). We assessed ECMM Quality of Clinical Candidaemia Management (EQUAL Candida) scores reflecting adherence to recommendations of the European Society of Clinical Microbiology and Infectious Diseases and the Infectious Diseases Society of America guidelines.

View Article and Find Full Text PDF

Spirituality is the human dimension that helps human beings to reflect about their own existence, to try to answer to questions like: what are we living for? This search of meaning is still more pronounced in those who suffer an advanced and incurable disease. This clear need is nevertheless not always acknowledge by the patient, making it difficult to detect and manage it in the daily care by healthcare professionals. In an effort to establish an effective therapeutic relationship, they have to keep in mind also this spiritual dimension, already integrated in the concept of comprehensive care and usually offered to all patients, especially in those who are at the end of life.

View Article and Find Full Text PDF

Melanoma arising in plaque-type blue nevus and dermal melanocytosis: Diagnostic and prognostic value of BAP1.

Actas Dermosifiliogr

July 2023

Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, España.

Melanoma arising in blue nevus, also known as melanoma ex blue nevus, is a specific form of melanoma whose genetic profile is different to that of other cutaneous melanomas and surprisingly similar to that of uveal melanoma. Although melanoma ex blue nevus can appear de novo, it usually arises in a preexisting blue nevus or dermal melanocytosis. Not all nodular lesions arising in association with blue nevus or dermal melanocytosis are melanomas, however, and because clinical and histologic findings may be insufficient for a definitive diagnosis, additional studies such as comparative genomic hybridization are important.

View Article and Find Full Text PDF